A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL - Trial NCT05950997
Access comprehensive clinical trial information for NCT05950997 through Pure Global AI's free database. This phase not specified trial is sponsored by The First Affiliated Hospital with Nanjing Medical University and is currently Not yet recruiting. The study focuses on Chronic Lymphocytic Leukemia. Target enrollment is 89 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The First Affiliated Hospital with Nanjing Medical University
Timeline & Enrollment
N/A
Aug 31, 2023
Sep 30, 2026
Primary Outcome
Progression-free survival rate at 24 months
Summary
This is a single-arm, prospective study to assess the efficacy and safety of acalabrutinib
 combined with obinutuzumab in subjects with previously untreated chronic lymphocytic
 leukemia.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05950997
Non-Device Trial